Press Releases | Regeneron Pharmaceuticals Inc.
WEBLatest Dupixent® (dupilumab) and Itepekimab Data at ERS Highlight Scientific Innovation and Leadership in Respiratory Diseases. Aug 20. Regeneron Provides Update on Biologics License Application for Linvoseltamab. Aug 7. Regeneron Announces Investor Conference Presentations and Oncology Investor Webcast. Aug 1.
Regeneron Announces Formation of Regeneron Cell Medicines …
WEBJan 30, 2024 · Regeneron Announces Formation of Regeneron Cell Medicines with the Acquisition of 2seventy bio Platforms and Preclinical and Clinical Programs. Regeneron to assume full development and commercialization rights for 2seventy bio’s preclinical and clinical stage cell therapy pipeline.
Regeneron to Highlight Progress Across Its Differentiated …
WEBSep 9, 2024 · A combined 11 presentations across both congresses highlight Regeneron’s commitment to transforming care for people living with difficult-to-treat cancers, including advanced melanoma, advanced non-melanoma skin …
Regeneron, SNY Win FDA Approval for a Broader Dupixent Label
WEB3 days ago · Regeneron Pharmaceuticals, Inc. REGN announced that the FDA has approved blockbuster drug Dupixent (dupilumab) for the indication of chronic rhinosinusitis with nasal polyps (CRSwNP) for a...
Regeneron Announces Encouraging Topline Phase 2 Data of High …
WEBAug 24, 2021 · Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that an ongoing Phase 2 proof-of-concept trial evaluating an investigational 8 mg dose of aflibercept met its primary safety endpoint, with no new safety signals observed compared to the currently-approved 2 mg dose of EYLEA ® (aflibercept) Injection in patients with …
Regeneron Announces New U.S. Government Agreement to …
WEBUnder the new agreement, Regeneron will supply an additional 1.4 million 1,200 mg doses of REGEN-COV to the U.S. government by January 31, 2022, at a cost of $2,100 per dose. This new agreement follows two earlier agreements with the U.S. government announced in July 2020 and January 2021.
News Release - Regeneron Pharmaceuticals Inc.
WEBSep 10, 2022 · Novel Regeneron Bispecific Antibodies Show Encouraging Anti-tumor Activity in Two Advanced Solid Tumors. First-in-class Phase 1 data presented at ESMO for ubamatamab (REGN4018; MUC16xCD3) in recurrent ovarian cancer and REGN5093 (METxMET) in MET-altered advanced non-small cell lung cancer.
Buy Rating Affirmed: Regeneron’s Growth Potential Anchored by …
WEB2 days ago · Evan Seigerman has given his Buy rating due to a combination of factors centered around Regeneron’s promising pipeline and market performance. He highlights the company’s growth in treatment ...
Dupixent receives FDA approval as first CRSwNP treatment
WEB3 days ago · Regeneron’s Dupixent approved as first adolescent CRSwNP treatment. The safety profile of Dupixent in adolescents with moderate-to-severe asthma contributed to the FDA's decision.
Regeneron's experimental gene therapy improves hearing in one …
WEBMay 8 (Reuters) - Regeneron Pharmaceuticals (REGN.O) said on Wednesday its investigational gene therapy improved hearing to normal levels in a child within 24 weeks in an early to mid-stage...
- Some results have been removed